All articles tagged with #weight management
A pilot study indicates that using a digital wellness app or receiving medically tailored meals can significantly reduce weight regain after stopping GLP-1 receptor agonists. While usual care led to a 10.75% weight regain over four months, intervention groups saw only about 3.6% regain. Experts emphasize that these strategies are not replacements for long-term medication but can aid transition.
A pilot study indicates that medically tailored meals and digital wellness apps can significantly reduce weight regain after patients stop GLP-1 medications, with control participants regaining 10.75% of body weight in four months compared to roughly 3.6% for intervention groups.
As GLP-1 medication use in the U.S. rises to 11%, experts warn that rapid weight loss can accelerate muscle loss. Exercise physiologist Heidi Skolnik advises users to focus on compound movements targeting large muscle groups to preserve strength and metabolic health.
As GLP-1 weight-loss medications become more common, physicians are increasingly managing patients who discontinue treatment due to cost, access, or side effects. This discontinuation often leads to weight regain, which can trigger depression, shame, and reduced engagement with healthcare. Experts advise clinicians to proactively screen for mood disorders, use non-judgmental language, and shift focus from scale weight to broader health metrics. Integrating behavioral health support and setting small, achievable goals can help patients maintain momentum and reduce the stigma associated with weight fluctuation.
Medical experts have raised concerns about President Donald Trump's recent weight gain, noting that he has added approximately 23 pounds since his last campaign. This increase, which brings his weight to around 238 pounds, has prompted warnings about potential health risks, including cardiovascular issues. While the White House maintains that the president remains energetic and cognitively fit, doctors emphasize the importance of diet and exercise for long-term health.
Early-stage studies suggest obesity drugs may help manage PMOS, a hormonal disorder, offering hope to affected families; further research is needed to confirm effectiveness and safety.
Britain’s MHRA approved Eli Lilly’s Foundayo (orforglipron) for weight management and type 2 diabetes, marking Lilly’s first European license for the oral GLP-1 drug. The EU decision is not expected until next year. An NHS coverage decision will be made by NICE on November 18, with initial access likely in the private market; Novo Nordisk’s Wegovy pill is expected to reach EU markets soon, increasing competition. The UK remains the only country with a bilateral deal with the US to pay more for medicines.
A University of Toronto study followed 74 overweight adults for 12 weeks and found that three daily servings of full-fat dairy did not cause weight gain or cholesterol increases; participants even showed lower blood pressure and higher intake of calcium, protein, and vitamin D, supporting a 'dairy matrix' view that the health effects come from the whole dairy structure rather than isolated nutrients.
Experts say GLP-1 weight-loss drugs can help, but weight is often regained after stopping. Long-term success depends on building sustainable eating and exercise habits with a dietitian, rather than relying solely on medication. Side effects like slowed digestion and nausea may occur, so ongoing medical guidance is important.
A Perspective published in The Journal of Nutrition analyzes the updated 2025–2030 Dietary Guidelines' protein recommendation of 1.2–1.6 g/kg/day. It acknowledges strengths such as a focus on high‑quality protein and potential weight‑management benefits for those with overweight/obesity, but argues the current evidence does not justify a universal higher‑protein intake for all Americans and calls for more diverse research across life stages and populations to strengthen future guidance.
A six‑week analysis cited in Annals of Internal Medicine shows that cutting about 80 minutes of sleep per night can cause roughly 0.45 kg (1 lb) weight gain, larger waistlines, and more sedentary behavior—even with a healthy diet and exercise. Dr. Sudhir Kumar emphasizes that sleep is a third pillar of weight management alongside diet and exercise, and most adults should aim for seven to nine hours of quality sleep nightly to protect metabolism, heart, and brain.
The American Heart Association coined CKM syndrome in 2023 to describe the overlap of cardiovascular, kidney, and metabolic diseases driven by excess weight, high blood pressure, and high blood sugar. It’s defined as a four‑stage continuum (Stage 0–Stage 4) with about 90% of Americans on the spectrum; prevention focuses on lifestyle changes (Mediterranean-style diet, physical activity, sleep, avoiding nicotine) and broad‑acting medications (GLP‑1s, SGLT2 inhibitors, nsMRAs) alongside traditional treatments like metformin, statins, and ACE inhibitors to slow progression and reduce hospitalizations. The overarching message is awareness and prevention, rather than overmedicalizing those at risk—including Stage 0 individuals who are at risk but not yet diseased.
Beginning Wednesday, Medicare will temporarily cover GLP-1 weight-loss drugs for seniors and certain disabled beneficiaries through an 18-month pilot, with a $50 monthly copay; coverage requires prior authorization and the program’s costs to taxpayers have not been disclosed. Covered drugs include Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy (including the Wegovy pill Foundayo). The move aims to curb obesity-related health risks but raises questions about long-term affordability and access.
Intermittent fasting is not a weight-loss diet but a structured eating window that rests the digestive system, reduces inflammation, and may improve insulin sensitivity, blood sugar, sleep, and mental energy; however, weight loss still depends on total calories and diet quality, and fasting isn’t ideal for athletes or during healing—use a consistent 8–12 hour window and tailor to your health needs.
An NIH-supported PATHWEIGH program implemented across 56 UCHealth primary care clinics and reaching about 274,000 patients reduced population weight gain by 0.58 kg over 18 months, increased weight-related care by 23%, and is being considered as a standard approach to obesity treatment in the U.S.